Just wait, Momenta CEO says. Novartis' generic can bring down Copaxone

Thanks to some aggressive brand defense tactics, Teva's ($TEVA) multiple sclerosis blockbuster Copaxone has been hanging onto its slice of the pie despite generic competition from Novartis' ($NVS) Sandoz and Momenta ($MNTA). But it's all a matter of time until Sandoz manages to cut down Teva's market share, Momenta CEO Craig Wheeler recently promised investors. Sandoz has "the capabilities necessary" and is "focused on countering" the Israeli drugmaker's strategy, he said. More from FiercePharmaMarketing

Read more on